NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Thanks again Flipper. Question for you. Something I've never understood, but I'm probably missing something really simple.

I understand how the WHO redefinition of GBM to exclude proneural tumors helps NWBO's data as our vaccine shows as more effective in mesenchymal/classical tumors. (side question, is the WHO definition also accepted by the FDA?)

You didn't state this here, but I've seen it from other posters that the redefinition actually increases the potential market of dcvax-L.

My question is, wouldn't this redefinition and LL's comments lead you to believe the potential market is actually being cut in half?

TIA